OCTAGON CAPITAL ADVISORS LP
Q2 2026 Form 13-F
NEW YORK, NEW YORK
CIK 0001839435
· CRD 306424
· SEC-registered investment adviser
$1.1B Reported Value Total
OCTAGON CAPITAL ADVISORS LP reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $1,175,272,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $1.2B gross asset value
Hedge Fund: $975.2M · Private Equity Fund: $200.1M
Source: Form ADV filed 2026-03-20
Reported value
$1.1B
Quarter over quarter
+28.9%
Holdings
26
Top-10 concentration
78.5%
Key People
Form ADV owners & control persons
Ting (nmn) Jia
FOUNDER, PORTFOLIO MANAGER, AND LIMITED PARTNER
Justin M Hirsch
CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $1.1B |
| Positions | 26 |
| Change in reported value | +23.1% |
| New positions | 4 |
| Exited positions | 7 |
| Position turnover | 33.3% |
| Top-10 concentration | 78.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
26 | $1.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
29 | $903.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
26 | $823.7M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
26 | $659.8M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
30 | $455.6M |
|
Q1 2025 13F
Filed May 15, 2025
|
34 | $516.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
31 | $607.7M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
41 | $642.9M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
44 | $636.3M |
|
Q1 2024 13F
Filed May 15, 2024
|
56 | $834.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
33 | $625.0M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
35 | $650.9M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
40 | $718.7M |
|
Q1 2023 13F
Filed May 15, 2023
|
35 | $695.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
32 | $642.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
35 | $579.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
20 | $374.7M |
|
Q1 2022 13F
Filed May 16, 2022
|
24 | $462.6M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
28 | $513.9M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
30 | $406.1M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | $179.5M | 16.14% |
| 2 | DFTX DEFINIUM THERAPEUTICS INC | $138.8M | 12.47% |
| 3 | ABVX ABIVAX SA | $132.3M | 11.89% |
| 4 | COGT COGENT BIOSCIENCES INC | $90.9M | 8.17% |
| 5 | ALMS ALUMIS INC | $79.7M | 7.16% |
| 6 | AVBP ARRIVENT BIOPHARMA INC | $68.5M | 6.15% |
| 7 | TSHA TAYSHA GENE THERAPIES INC | $66.0M | 5.93% |
| 8 | BIOA BIOAGE LABS INC | $42.8M | 3.85% |
| 9 | MIRM MIRUM PHARMACEUTICALS INC | $39.7M | 3.57% |
| 10 | KYMR KYMERA THERAPEUTICS INC | $35.5M | 3.2% |
| 11 | AKTS AKTIS ONCOLOGY INC | $31.0M | 2.78% |
| 12 | XENE XENON PHARMACEUTICALS INC | $29.6M | 2.66% |
| 13 | ERAS C ERASCA INC | $23.0M | 2.07% |
| 14 | PALI PALISADE BIO INC | $21.5M | 1.93% |
| 15 | OCUL OCULAR THERAPEUTIX INC | $20.4M | 1.83% |
| 16 | IRON DISC MEDICINE INC | $19.7M | 1.78% |
| 17 | SMMT SUMMIT THERAPEUTICS INC | $18.2M | 1.64% |
| 18 | PHVS PHARVARIS N V | $15.8M | 1.42% |
| 19 | ANL ADLAI NORTYE LTD | $10.7M | 0.97% |
| 20 | DTIL PRECISION BIOSCIENCES INC | $10.6M | 0.95% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.